GNPX insider trading
NasdaqCM HealthcareGenprex, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Genprex, Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is based in Austin, Texas.
Company website: www.genprex.com
GNPX insider activity at a glance
FilingIQ has scored 41 insider transactions for GNPX since Mar 29, 2018. The most recent filing in our index is dated Apr 14, 2026.
Across the full history, 8 open-market purchases
and 2 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on GNPX insider trades is 63.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for GNPX?
- FilingIQ tracks 41 Form 4 insider transactions for GNPX (Genprex, Inc.), covering filings from Mar 29, 2018 onwards. 4 of those were filed in the last 90 days.
- Are GNPX insiders net buyers or net sellers?
- Across the full Form 4 history for GNPX, 8 transactions (20%) were open-market purchases and 2 (5%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does GNPX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is GNPX in?
- Genprex, Inc. (GNPX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.12M.
Methodology & sources
Every GNPX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.